Santhera Pharmaceuticals (Switzerland) Insiders
| SANN Stock | CHF 15.76 0.30 1.87% |
Santhera Pharmaceuticals employs about 39 people. The company is managed by 10 executives with a total tenure of roughly 91 years, averaging almost 9.0 years of service per executive, having 3.9 employees per reported executive. Recap of Santhera Pharmaceuticals' management performance can provide insight into the venture performance.
| Eva Kalias Insider Head Communications |
| FCMA CGMA Insider Chief Officer |
Santhera |
Santhera Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4918) % which means that it has lost $0.4918 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.1615) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Santhera Pharmaceuticals Workforce Comparison
Santhera Pharmaceuticals Holding is rated fourth in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 477. Santhera Pharmaceuticals holds roughly 39.0 in number of employees claiming about 8% of stocks in Biotechnology industry.
Santhera Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Santhera Pharmaceuticals Price Series Summation is a cross summation of Santhera Pharmaceuticals price series and its benchmark/peer.
Santhera Pharmaceuticals Notable Stakeholders
A Santhera Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Santhera Pharmaceuticals often face trade-offs trying to please all of them. Santhera Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Santhera Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eva Kalias | Head Communications | Profile | |
| FCMA CGMA | Chief Officer | Profile | |
| Shabir MD | Chief Officer | Profile | |
| Thomas Meier | Founder Chairman | Profile | |
| Dario Eklund | Chief Officer | Profile | |
| Neville MD | Head Management | Profile | |
| Gnther Metz | Head VP | Profile | |
| Sarah HolmesKlotz | Head Culture | Profile | |
| Oliver Strub | Gen VP | Profile | |
| Marc Schrader | Head Operations | Profile |
About Santhera Pharmaceuticals Management Performance
The success or failure of an entity such as Santhera Pharmaceuticals often depends on how effective the management is. Santhera Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Santhera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Santhera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.
Please note, the imprecision that can be found in Santhera Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Santhera Pharmaceuticals Holding. Check Santhera Pharmaceuticals' Beneish M Score to see the likelihood of Santhera Pharmaceuticals' management manipulating its earnings.
Santhera Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Santhera Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Santhera Pharmaceuticals within its industry.Santhera Pharmaceuticals Manpower Efficiency
Return on Santhera Pharmaceuticals Manpower
| Revenue Per Employee | -40.9K | |
| Revenue Per Executive | -159.5K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 5.6M |
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.